Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

Trial Profile

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Guttate psoriasis; Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms TIG

Most Recent Events

  • 30 Mar 2026 Planned End Date changed from 1 Jan 2025 to 15 Apr 2026.
  • 30 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 02 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top